Women's Health · FAQ
GLP-1 Weight-Loss Medication for Women: Every Question, Answered With Sources
This page answers the questions women actually ask — and ask AI assistants — about GLP-1 weight-loss medication (semaglutide and tirzepatide): real trial results, honest costs, side effects, the 2026 compounding crackdown, and how to pick a telehealth program. Every answer links to its primary source: a peer-reviewed trial, the FDA, the FTC, or a named dataset.
Results
How much weight do women actually lose on semaglutide?
In the pivotal STEP 1 trial (1,961 adults, roughly three-quarters women), weekly semaglutide 2.4 mg produced an average loss of 14.9% of body weight over 68 weeks, versus 2.4% on placebo. About a third of participants lost 20% or more; some lost much less. Details and caveats: our full breakdown of the trial data.
How much weight do people lose on tirzepatide?
More, on average. In SURMOUNT-1, the highest tirzepatide dose averaged 20.9% body-weight loss over 72 weeks. And in the first true head-to-head trial (published in the NEJM, 2025), tirzepatide beat semaglutide on average loss over 72 weeks. Tirzepatide is typically the more expensive option — the trade-off is real.
How fast do GLP-1s work?
Gradually, by design — doses are escalated over months to manage side effects, loss is fastest in the early-to-middle months, and the trial averages above are measured at 68–72 weeks (about a year and a half). Any program promising a specific number of pounds "by summer" is marketing against the clock the evidence doesn't support; the FTC's false weight-loss claims guide is worth five minutes before you believe any ad in this category.
Is there a GLP-1 pill now, or is it injections only?
There are now two FDA-approved pills. Oral semaglutide 25 mg (Wegovy tablets) reached US pharmacies in January 2026 — in the OASIS 4 trial (307 adults, 242 of them women), mean body-weight change at 64 weeks was −13.6% versus −2.2% on placebo, an estimated difference of 11.4 percentage points. Novo Nordisk's release separately quotes "16.6% mean weight loss when treatment was adhered to" — a different statistical estimand, published with no placebo comparator, so it is not interchangeable with the trial's primary result. Foundayo (orforglipron), approved April 1, 2026, is the first small-molecule GLP-1 pill; in ATTAIN-1 (3,127 adults) it averaged −11.2% at the top dose versus −2.1% on placebo over 72 weeks, with 54.6% losing at least 10% of body weight. These are different trials with different designs, so the numbers aren't head-to-head. Full comparison, including how the pills stack up against injections: the GLP-1 pill era, explained. "Oral semaglutide" drops, troches, and kits sold outside these approved products remain unapproved.
Which GLP-1 pill works better — Foundayo or oral Wegovy?
For weight loss, nobody knows: no trial has compared them in people with obesity. The only published head-to-head, ACHIEVE-3 (1,698 adults, 52 weeks), was a type 2 diabetes trial, and it used the diabetes doses of semaglutide (7 and 14 mg Rybelsus tablets), not the 25 mg weight-management tablet. In it, orforglipron 36 mg lowered A1c more than oral semaglutide 14 mg (−1.91% vs −1.47% from a baseline of 8.3%) and produced more weight loss — −9.2% vs −5.3% from a baseline of 97.0 kg — but roughly twice as many participants stopped because of side effects (41 of 423 on orforglipron 36 mg vs 21 of 425 on semaglutide 14 mg). Weight was a secondary endpoint there, and the same GLP-1 reliably produces less weight loss in people with diabetes than without, so those percentages are not what a woman without diabetes should expect. Our full read of that trial: what the first pill-versus-pill trial actually showed; the two approved pills side by side: the GLP-1 pill era, explained.
Will I regain the weight if I stop?
Most people regain a substantial share. In the SURMOUNT-4 withdrawal trial, participants switched to placebo after 36 weeks regained much of their lost weight while those who continued kept losing. Clinically, obesity treatment with GLP-1s behaves like chronic-disease management — factor the ongoing cost into the decision from day one.
Safety
What are the side effects for women?
Mostly gastrointestinal — nausea, diarrhea, constipation, vomiting — usually transient and mild-to-moderate, but not trivial: in STEP 1, 4.5% of the semaglutide group discontinued because of GI events, versus 0.8% on placebo. Rarer but serious risks (pancreatitis, gallbladder disease) are screened for by any legitimate prescriber, which is one reason "prescription in 5 minutes" is a red flag, not a feature. Full breakdown: GLP-1 side effects in women.
Do GLP-1s cause vision problems?
European regulators concluded in June 2025 that NAION — a rare optic-nerve condition causing sudden, usually permanent partial vision loss in one eye — is a "very rare" side effect of semaglutide, meaning it may affect up to 1 in 10,000 people. The scale matters: EMA put it at roughly one additional case per 10,000 person-years of treatment in adults with type 2 diabetes. A 2026 meta-analysis in Ophthalmology found 26.7 cases per 100,000 person-years on semaglutide versus 18.9 without it in observational diabetes data, while the randomized trials were too small to confirm or rule out an effect. Guidance from both EMA and the WHO: contact a doctor without delay for sudden vision loss or rapidly worsening eyesight; semaglutide is stopped only if NAION is confirmed. Do not stop on your own. Full analysis: what the NAION evidence actually shows.
Can I take a GLP-1 while pregnant or trying to conceive?
No. GLP-1 medications are not for use during pregnancy, and clinicians advise stopping in advance of trying to conceive. A telehealth intake that doesn't ask about pregnancy plans is telling you something about its medical oversight.
Is compounded semaglutide safe — and is it even legal in 2026?
It occupies a shrinking legal gray zone. Compounded GLP-1s are not FDA-approved — the agency has logged 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, many involving dosing errors — and in March 2026 the FDA warned 30 telehealth companies over misleading GLP-1 marketing, with regulators moving to close large-scale compounding entirely. On April 30, 2026 the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the list that lets outsourcing facilities compound them in bulk; the public comment period, extended once by the agency from June 29, closes July 30, 2026. After that date the FDA must review what was submitted before it can issue a final rule, and it has announced no timeline for one — so until a final rule takes effect, the legal position is unchanged. Patients aren't the enforcement target, but the supply can vanish with one warning letter. Full explainer: compounded vs branded in 2026; the latest on the rulemaking: our news coverage.
What happens if my compounded supply disappears?
Have a continuity plan before you need it: know which branded product and provider you'd switch to, and what it costs. Don't stop abruptly without clinical advice — and see the regain data above for why an unplanned stop is costly.
Are peptides like BPC-157 legal in the US now?
No — and nothing about their legal status changed in July 2026, despite headlines suggesting otherwise. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven nominated peptides for the 503A bulk drug substances list — the list of ingredients compounding pharmacies may use. BPC-157 passed 8–6 with one abstention on July 23, per ABC News. Three things that vote did not do. It is advisory and non-binding — the FDA's own meeting notice states that advisory committees "make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." Actual listing requires FDA action through public rulemaking, a lengthy process that has not begun. And listing for compounding is not FDA approval: it would never make BPC-157 an approved drug or establish that it works. FDA's own staff reviewers concluded the criteria "weigh against" listing BPC-157, citing thin human evidence — they identified a single trial of 46 participants, in which the peptide was given as an enema rather than by the injection route under consideration. Until then, vials sold online remain unapproved products of unverified content. What a peptide actually is: one word, three different markets. The BPC-157 evidence in full: what the human data shows and what the vote changed.
Costs and access
How much does GLP-1 treatment cost without insurance?
It ranges from roughly $100–$200/month for compounded programs (with the legal and supply caveats above) to several hundred per month for branded medication, with manufacturer direct-purchase programs having meaningfully narrowed the gap for cash payers. Treat any price you see as provisional until you've confirmed what it includes — medication, clinician visits, and dose escalations are bundled by some programs and billed separately by others. Our program comparison flags the pricing model for each.
Do I need insurance to get a prescription online?
No — direct-pay telehealth is how most of this market now works: an online medical intake, a licensed clinician review, and (if appropriate) a prescription filled by mail. Insurance coverage for weight-loss GLP-1s remains patchy, which is exactly why the cash-pay market is so large.
Does Medicare cover GLP-1s for weight loss now?
As of July 1, 2026 — partially, through a temporary program. Medicare Part D is barred by statute from covering drugs prescribed for weight loss alone, but the new Medicare GLP-1 Bridge demonstration, per KFF's analysis, lets eligible beneficiaries get Wegovy (injection or tablet), Foundayo, or Zepbound (KwikPen) for a $50-per-month copay through December 31, 2027, with a provider prior authorization and BMI/clinical criteria. Medicaid coverage of weight-loss drugs remains optional for states — KFF counts only 13 states covering them as of January 2026 — and employer coverage remains patchy. The full picture, including how to check your own plan: our 2026 insurance coverage guide.
How common is GLP-1 use in the US?
Mainstream and still growing: Gallup's mid-2026 survey found 11% of US adults currently taking a GLP-1 for weight loss — up from 3% in 2024 — and 15% having used one at some point. That squares with KFF's May 2024 polling, which found about 1 in 8 US adults had already tried one. Gallup's tracking also shows the US adult obesity rate falling to 36.4% so far in 2026 from a 39.9% peak in 2022 — a self-reported survey estimate, examined in our analysis of what those numbers show.
Choosing a program
How do I choose a GLP-1 telehealth program?
Four questions separate the field: Is the medication branded or compounded (a legal-risk question in 2026, not just a price question)? Is the clinician interaction real (screening, dose management) or rubber-stamp? Is pricing all-inclusive or à la carte? And does the marketing quote trials or fantasies? We scored seven programs on exactly these axes in the 2026 comparison for women.
Are the before/after photos and testimonials on weight-loss sites real?
Assume unverifiable. Fabricated testimonials are common enough that the FTC publishes a spotting guide, and no ad photo tells you the average result — only trials do. (Our own editorial policy bans testimonials entirely; we cite trials.)
Where should I start?
With the honest numbers (what the trials show), then the regulatory reality (compounded vs branded), then the program comparison — and ultimately with a licensed clinician who reviews your health history, because that's whose call a prescription is.